Glucagon-like peptide (GLP)-1 is a gastrointestinal peptide hormone with role in insulin secretion, contains N-terminal biotin tag
Catalogue number crb1000881 Molecular Weight 4335.1 Sequence (one letter code)
Sequence (three letter code)
Aliase [Biotin]-GLP-1 Purity >95% References
Graaf et al., (2016). Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol. Rev., 68(4): 954. PMID: 27630114.
Manandhar and Ahn (2014). Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications. J. Med. Chem., 58(3): 1020. PMID: 25349901.
Manufactured in: United Kingdom
Glucagon-like peptide (GLP)-1 is a gastrointestinal peptide hormone with multiple roles in relation to metabolism. The primary role of GLP-1 is increasing insulin secretion in the presence of high plasma glucose levels, in addition, GLP-1 also suppresses glucagon secretion from the pancreas. GLP-1 slows down gastric emptying and regulates appetite, both valuable in reducing food intake and body weight. These roles of GLP-1 make it a useful target in the management of type 2 diabetes mellitus (T2DM).
GLP-1 exerts its effects by binding to and activating the class B G protein–coupled receptor (GPCR): GLP-1 receptor (GLP-1R). Receptor activation in turn activates signalling pathways which culminates in insulin secretion via CAMP and Ca2+ signalling.
Recently evidence has increased for GLP-1 playing a cardio-protective role as well as regulating immune responses and even in kidney function. GLP-1 may also exert neuroprotective and neurotropic effects as it can decrease endogenous levels of amyloid-beta (Aβ) and prevent Aβ-induced cell death.
This peptide contains an N-terminal Biotin tag for simple detection and purification.